Advances in the treatment of diabetes mellitus in the elderly: Development of insulin analogues

Drugs and Aging

Volumn 9, Issue 6, 1996, Pages 438-448

  Hoogwerf, Byron J ^a   Mehta, Adi ^a   Reddy, Sethu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; UNCLASSIFIED DRUG;

AGED; DIABETES MELLITUS; DRUG ABSORPTION; DRUG STABILITY; DRUG STRUCTURE; HISTORY OF MEDICINE; HUMAN; INSULIN RELEASE; INSULIN TREATMENT; ISOELECTRIC POINT; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

EID: 0030478225     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609060-00006     Document Type: Review

References (65)

1. Bliss M. The discovery of insulin. Chicago: The University of Chicago Press, 1982
2. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8
3. Brange J, Owens DR, Kang S, et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-54
4. Bratusch-Marrain PR, Komjati M, Waldhaust WK. Efficiency of pulsatile versus continuous insulin administration on hepatic glucose utilization in type I diabetic humans. Diabetes 1986; 35: 922-6
5. Ward WK, Bolgiano DC, McKnight B, et al. Diminished beta-cell secretory capacity in patients with non-insulin dependent DM. J Clin Invest 1984; 74: 1318-28
6. Ferrannini E, Simonson DC, Katz LD, et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 1988; 37: 79-85
7. Butler PC, Rizza RA. Contribution to post-prandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991; 40: 73-81
8. Bruce DG, Chisholm DJ, Storlein LH, et al. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-44
9. Drucker D, Zinman B. Pathophysiology of beta-cell failure after prolonged remission in insulin-dependent DM. Diabetes Care 1984; 1: 83-7
10. Hoogwerf BJ, Rich SJ, Barbosa JJ. Meal stimulated C-peptide response and insulin antibodies in type I diabetic subjects and non-diabetic siblings and characterized by HLA DR antigens. Diabetes 1985; 34: 440-5
11. Bushhouse SA, Goetz FC, Jacobs DR, et al. C-peptide response to meal challenge in non-diabetic and diabetic adults living in Wadena, Minnesota. Diabetes Care 1992; 15: 1335-47
12. French LR, Goetz FC, Martinez AM, et al. Association between stimulated plasma C-peptide and age: the Wadena City Health Study. J Am Geriatr Soc 1992; 40: 309-15
13. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)] - human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
14. Volund AA, Brange J, Drejer K, et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 1991; 8: 839-47
15. Kang S, Creagh FM, Pteres JR, et al. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991; 14: 571-7
16. Markussen J, Diers I, Hougaard P, et al. Soluble, prolonged-acting insulin derivatives: III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 1988; 2: 157-66
17. Monti LD, Poma R, Caumo I, et al. Intravenous infusion of diarginylinsulin, as insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism 1992; 41: 540-4
18. Heinemann L, Heise T, Jornegsen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28asp. Diabet Med 1993; 10: 535-9
19. Markussen J, Hougaard P, Ribel U, et al. Soluble, prolonged-acting insulin derivatives: I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng 1987; 1: 205-13
20. Svoboda I, Brandenburg D, Barth T, et al. Semisynthetic insulin analogues modified in positions B24, B25, and B29. Biol Chem Hoppe Seyler 1994; 375 (6): 373-8
21. Kobayashi M, Takata Y, Ishibashi O, et al. Receptor binding and negative cooperativety of mutant insulin. [leuA3] - insulin. Biochem Biophys Res Commun 1986; 137: 250-7
22. Schwartz GP, Burke GT, Katsoyannis PG. A superactive insulin: [B10-aspartic acid] insulin (human). Proc Natl Acad Sci U S A 1987; 84: 6408-11
23. Leahy J, Vandekerkhove KM. Insulin-like growth factor-1 at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 1990; 126: 1593-8
24. Zenobi PD, Graf S, Ursprung H, et al. Effects of insulin-like growth factor-1 on glucose tolerance, insulin levels and insulin secretion. J Clin Invest 1992; 89: 1908-13
25. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al. Insulin-like growth factor-1 improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-41
26. Zenobi PD, Holzmann P, Glatz Y, et al. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor. Diabetologia 1993; 36: 465-9
27. Froesch ER, Zenobi PD, Hussain M, Metabolic and therapeutic effects of insulin-like growth factor. Hormone Res 1994; 42: 66-71
28. Sinha MK, Buchanan C, Leggett N, et al. Mechanism of IGF-1-stimulated glucose transport in human adipocytes: demonstration of specific IGF-1 receptors not involved with glucose transport. Diabetes 1989; 38: 1217-25
29. Bornfeldt KE, Gidlof RA, Wasteson A, et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells: comparison of maximal growth promoting activities. Diabelologia 1991; 34: 307-13
30. Dills DG, Moss SE, Klein R, et al. Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991; 40: 1725-30
31. Drejer K. The bioactivity of insulin analogues from in vitro receptor bindine to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259-86
32. Vignati L, Brunelle RL. Treatment of 722 patients with type II diabetes with insulin lispro in a 6 month crossover study [abstract]. Diabetes 1995; 44 Suppl. 840: 229A
33. Antsiferov M, Woodworth JR, Mayorov A, et al. Lower within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin [abstract]. Diabetes 1995; 44 Suppl. 777: 214A
34. Torlone E, Pampanelli S, Lalli C, et al. Effects of the short-acting insulin analog [Lys(B28). Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-52
35. Pampanelli S, Torlone E, Lalli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995; 18: 1452-9
36. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analog insulin lispro vs. Humulin R insulin treatment in young subjects with type I diabetes. Diabetic Med 1996; 13: 47-52
37. Heinemann L, Heise T, Wahl LC, et al. Prandial glycemia after a carbohydrate-rich meal in type-I diabetic patients using the rapid acting insulin analog (Lyst B28), Pro(B29) human insulin. Diabetic Med 1996; 13: 625-9
38. Coates PA, Mukherjee S, Luzio S, et al. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE-901) in healthy subjects [abstract]. Diabetes 1995; 44 Suppl. 478: 130A
39. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12: 464-74
40. Flatt PR, Barnett CR, Swanston-Flatt SK. Mechanisms of pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes. Biochem Soc Trans 1994; 22 (1): 18-23
41. Rosetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13 (6): 610-30
42. National Center for Health Statistics. The national nursing home survey, 1985. Hyattsville (MD): National Center for Health Statistics, 1985: (Stock #017-022-010-658)
43. Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly. Diabetes Care 1992; 15: 1628-30
44. Kerr D, Haigh R. Intensive diabetes treatment: a new deal for older people [commentary]. Age Ageing 1994; 23: 89-90
45. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13: 1240-64
46. Alberti KGMM, Gries FA. Management of noninsulin dependent DM in Europe. Diabet Med 1988; 5: 275-81
47. Taylor R, Foster B, Kyne-Grzebalski D, et al. Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life. Diabet Med 1994; 11: 551-7
48. Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 1990; 13: 1209-39
49. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med 1985; 2: 45-53
50. Meneilly GS, Elahi D, Minaker KL, et al. The dawn phenomenon does not occur in normal elderly subjects. J Clin Endocrinol Metab 1986; 63: 292-6
51. Niskanen L, Lahti J, Uusitupa M. Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents. Diabetes Res Clin Pract 1992; 18: 185-90
52. Longnecker MP, Elsenhans VS, Leiman SM, et al. Insulin and a sulfonylurea agent in non-insulin dependent DM. Arch Intern Med 1986; 146: 673-6
53. Allen BT, Feinglos MN, Lebovitz HE. Treatment of poorly regulated non-insulin-dependent DM with combination insulin-sulfonylurea. Arch Intern Med 1985; 145: 1900-3
54. Quatraro A, Giugliano D. The combination of insulin and oral by poglycaemic drugs: a continuous challenge. Diabete Metab 1993; 19: 219-24
55. Quatraro A, Consoli G, Minei A, et al. The combined insulin and sulfonylurea therapy in diabetes of elderly people. Arch Gerontol Geriatr 1991; 13: 245-54
56. Kyllastynen M, Groop L. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type II) diabetic patients. Ann Clin Res 1985; 17: 100-4
57. Wolffenbuttel BH, Drossaert CH, Visser AP. Determinants of injecting insulin in elderly patients with type II DM. Patient Educ Couns 1993; 22: 117-25
58. UK Prospective Diabetes Study Group (UKPDS). UKPDS VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-90
59. UK Prospective Diabetes Study Group. UKPDS (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed tor 3 years. BMJ 1995; 31: 83-8
60. UK Prospective Diabetes Study Group. UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
61. Zappella A. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care 1992; 15: 1628-30
62. Aronoff S, Golderber R, Kumar D, et al. Use of premixed insulin regimen (Novolin 70/30) to replace self-mixed insulin regimens. Clin Ther 1994; 16: 41-9
63. Kabadi UM, Kabadi M. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea. J Fam Pract 1991; 33: 349-53
64. Cucinotta D, Mannino D, Lasco A, et al. Premixed insulin at ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control. Diabete Metab 1991; 17: 49-54
65. Buchwald H, Barbosa J, Varco RL, et al. Treatment of a type II diabetic by a totally implantable insulin infusion device. Lancet 1981; 1: 1233-4